HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

The study follows a Simon's two-stage phase II trial design to evaluate the safety and efficacy of tafasitamab added to rituximab and lenalidomide for two treatment-naïve, parallel, independent cohorts: follicular lymphoma (FL) and marginal zone lymphoma (MZ). Each cohort, FL and MZ, will be evaluated separately. This study is presented to the patient and consent is signed prior to the initiation of treatment for their primary malignancy.

Trial Details

NCT ID
NCT06792825
Phase
PHASE2
Sponsor
Masonic Cancer Center, University of Minnesota
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Tafasitamab
  • Rituximab
  • Lenalidomide
Locations (sample)
  • Minneapolis, Minnesota, United States|44.97997,-93.26384

Key Eligibility Criteria

  • Histologically confirmed marginal zone lymphoma
  • Histologically confirmed CD20+ follicular lymphoma stage 1, 2 or 3a
  • No prior systemic therapy for lymphoma
  • Must be in need of treatment as evidenced by one or more of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →